Clinical Trial

A Phase II, Nonrandomized, Single-Arm Study of Elranatamab Outpatient Administration in Patients with Relapsed/Refractory Multiple Myeloma

MOA; Elranatamab is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate malignant plasma cells in MM.

Key Eligibility:

• Documented diagnosis of relapsed/refractory MM according to IMWG criteria
  • Must have received ≥1 prior LOT that includes both
    lenalidomide and an anti-CD38 mAb(in the same or
    separate prior lines)
• Must have measurable disease at screening
• Subjects must be able and willing to receive prophylaxis for VZV and PJP
• Subjects with the following plasma cell disorders are excluded:
  active plasma cell leukemia, Waldenström’s macroglobulinemia,
  POEMS syndrome, or primary AL amyloidosis
• Subjects with active CNS multiple myeloma involvement are
  excluded